Editas Medicine News

Express News | Editas Medicine Inc: Extension Also Has Options to Extend Collaboration for up to an Additional Two Year

ReutersMay 1 08:02 ET

Express News | Editas:2 Yr Extension Collaboration With Bristol Myers,Parties May Research, Develop,Commercialize Autologous, Allogeneic Alpha-Beta T Cell Medicines

ReutersMay 1 08:02 ET

Express News | Editas Medicine Inc: Under Collaboration, Bristol Myers Squibb Has Opted Into 13 Different Programs Across 11 Gene Targets to Date

ReutersMay 1 08:00 ET

Express News | Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration

ReutersMay 1 08:00 ET

EDIT, CLNE and NIU Are Among After Hour Movers

Seeking AlphaApr 26 17:00 ET

Editas Medicine, Inc. (NASDAQ:EDIT) Looks Inexpensive After Falling 25% But Perhaps Not Attractive Enough

To the annoyance of some shareholders, Editas Medicine, Inc. (NASDAQ:EDIT) shares are down a considerable 25% in the last month, which continues a horrid run for the company. Instead of being rewar

Simply Wall StApr 23 08:04 ET

Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in Vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting

CAMBRIDGE, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a clinical-stage gene editing company, today announced that three abstracts have been accepted for presentation, including one

GlobeNewswireApr 22 16:31 ET

Leber Congenital Amaurosis Pipeline Insight 2024, Featuring Key Players ProQR Therapeutics, Editas Medicine, Atsena Therapeutics, Applied Genetic Technologies, IVERIC Bio and MeiraGTx

Yahoo FinanceApr 22 07:51 ET

Possible Bearish Signals With Editas Medicine Insiders Disposing Stock

The fact that multiple Editas Medicine, Inc. (NASDAQ:EDIT) insiders offloaded a considerable amount of shares over the past year could have raised some eyebrows amongst investors. When evaluating in

Simply Wall StApr 6 08:06 ET

Biotech Roundtable: Who Will Bring the Next CRISPR Drug to Market?

Seeking AlphaApr 2 11:36 ET

Biotech Roundtable: Is CRISPR All Its Cracked up to Be?

Seeking AlphaMar 26 11:43 ET

Editas Medicine, Inc. (EDIT) Presents at Barclays 26th Annual Global Healthcare Conference (Transcript)

Editas Medicine, Inc. (EDIT) Presents at Barclays 26th Annual Global Healthcare Conference (Transcript)

Earnings Call TranscriptsMar 13 19:58 ET

Editas Medicine, Inc. (EDIT) Leerink Partners Global Biopharma Conference (Transcript)

Editas Medicine, Inc. (EDIT) Leerink Partners Global Biopharma Conference (Transcript)

Earnings Call TranscriptsMar 12 15:56 ET

Editas Medicine, Inc. (NASDAQ:EDIT) Surges 28% Yet Its Low P/S Is No Reason For Excitement

Editas Medicine, Inc. (NASDAQ:EDIT) shareholders are no doubt pleased to see that the share price has bounced 28% in the last month, although it is still struggling to make up recently lost ground.

Simply Wall StMar 9 07:02 ET

1 Wall Street Analyst Raises Editas Medicine's Price Target by 45%. Here's Why She's Right.

The Motley FoolMar 7 03:31 ET

Editas Medicine, Inc. (EDIT) TD Cowen 44th Annual Healthcare Conference (Transcript)

Editas Medicine, Inc. (EDIT) TD Cowen 44th Annual Healthcare Conference (Transcript)

Earnings Call TranscriptsMar 6 17:05 ET

Insider Sells Shares of Editas Medicine Inc (EDIT)

Yahoo FinanceMar 5 23:52 ET

Editas Medicine (EDIT) Receives a New Rating From a Top Analyst

TipRanksMar 5 07:25 ET

1 Beaten-Down Stock With 55% Upside, According to Wall Street

Yahoo FinanceMar 4 10:30 ET

Why Editas Medicine Stock Soared as Much as 42% Higher This Week

The Motley FoolMar 2 21:49 ET